Since an overexpression of 2-hydroxyglutarate is a direct result of the IDH gene mutation, 2-hydroxyglutarate currently stands as an excellent metabolic predictor of IDH-mutated gliomas or low-grade gliomas [77]. The gene discussed is IDH1; the disease is central nervous system cancer.